CSIMarket



China Biologic Products Holdings Inc   (CBPO)
Other Ticker:  
 

China Biologic Products Holdings Inc 's Working Capital Ratio

CBPO's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




CBPO Working Capital Ratio (Dec 31 2019)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2018)
IV. Quarter
Y / Y Current Liabilities Change -2.48 % -2.48 % -2.48 % -2.48 % 25.31 %
Y / Y Current Assets Change -4.23 % -4.23 % -4.23 % -4.23 % 128.82 %
Working Capital Ratio MRQ 10.89 10.89 10.89 10.89 11.09
Overall Ranking # 388 # 379 # 0 # 0 # 226
Seq. Current Liabilities Change 0 % 0 % 0 % -2.48 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % -4.23 % 0 %



Working Capital Ratio forth quarter 2019 Comment
Regardless of the sequential decrease in Current Liabilities, Working Capital Ratio detoriated to 10.89 below company average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 44 other companies have achieved higher Working Capital Ratio than China Biologic Products Holdings Inc in forth quarter 2019. While Working Capital Ratio total ranking has deteriorated compare to the prior quarter from 379 to 388.

Explain Working Capital Ratio
Where is CBPO most successful ?
Working Capital Ratio CBPO on the trailing twelve month basis
Working Capital Ratio forth quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 45
Healthcare Sector # 134
Overall Market # 388


Working Capital Ratio Statistics
High Average Low
11.09 6.27 2.14
(Dec 31 2018)   (Sep 30 2014)




Financial Statements
China Biologic Products Holdings Inc 's Current Liabilities $ 119 Millions Visit CBPO's Balance sheet
China Biologic Products Holdings Inc 's Current Assets $ 1,300 Millions Visit CBPO's Balance sheet
Source of CBPO's Sales Visit CBPO's Sales by Geography


Cumulative China Biologic Products Holdings Inc 's Working Capital Ratio

CBPO's Working Capital Ratio for the trailling 12 Months

CBPO Working Capital Ratio

(Dec 31 2019)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2018)
IV. Quarter
Y / Y Current Liabilities TTM Growth -2.48 % -2.48 % -2.48 % -2.48 % 25.31 %
Y / Y Current Assets TTM Growth -4.23 % -4.23 % -4.23 % -4.23 % 128.82 %
Working Capital Ratio TTM 10.89 10.94 10.99 11.04 11.09
Total Ranking TTM # 270 # 270 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % -2.48 % 0 %
Seq. Current Assets TTM Growth 0 % 0 % 0 % -4.23 % 0 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis In spite of the year on year decrease in CBPO's average Current Liabilities to $119.31 millions, Working Capital Ratio to 10.89 below company average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 26 other companies have achieved higher Working Capital Ratio than China Biologic Products Holdings Inc . While overall ranking remained unchanged compare to previous quarter at no. 270.

Explain Working Capital Ratio
Where is CBPO most successful ?
Working Capital Ratio CBPO on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 104
Within the Market # 270


TTM Working Capital Ratio Statistics
High Average Low
11.09 5.2 2.46
(Dec 31 2018)   (March 31, 2015)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2019, within Biotechnology & Pharmaceuticals Industry Working Capital RatioDec 31 2019 MRQ Current AssetsDec 31 2019 MRQ Current Liabilities
Springworks Therapeutics Inc.  27.68 $ 331.361  Millions$ 11.970  Millions
Infinity Pharmaceuticals Inc.  27.50 $ 44.581  Millions$ 1.621  Millions
Oyster Point Pharma Inc.  26.33 $ 142.180  Millions$ 5.399  Millions
Igm Biosciences Inc.  26.04 $ 231.100  Millions$ 8.875  Millions
Strongbridge Biopharma plc  25.08 $ 83.543  Millions$ 3.331  Millions
Dyadic International Inc  23.61 $ 35.639  Millions$ 1.509  Millions
Gossamer Bio Inc.  23.17 $ 409.317  Millions$ 17.665  Millions
Homology Medicines Inc  21.54 $ 266.577  Millions$ 12.374  Millions
Aptose Biosciences Inc.  19.68 $ 98.766  Millions$ 5.018  Millions
Eidos Therapeutics Inc   18.78 $ 195.920  Millions$ 10.430  Millions
Lixte Biotechnology Holdings Inc.  18.61 $ 2.672  Millions$ 0.144  Millions
Madrigal Pharmaceuticals Inc.  17.74 $ 440.197  Millions$ 24.815  Millions
Crispr Therapeutics Ag  17.29 $ 987.547  Millions$ 57.106  Millions
89bio Inc.  17.00 $ 95.326  Millions$ 5.609  Millions
Scpharmaceuticals Inc.  15.66 $ 75.647  Millions$ 4.830  Millions
Protokinetix Incorporated  14.83 $ 0.378  Millions$ 0.026  Millions
Satsuma Pharmaceuticals Inc.  14.40 $ 114.744  Millions$ 7.971  Millions
Repligen Corp  14.34 $ 641.828  Millions$ 44.756  Millions
Enzon Pharmaceuticals inc.  14.17 $ 5.993  Millions$ 0.423  Millions
G1 Therapeutics Inc.  13.71 $ 271.003  Millions$ 19.769  Millions
Biomx Inc.  13.58 $ 84.531  Millions$ 6.224  Millions
Acceleron Pharma inc  13.48 $ 449.916  Millions$ 33.373  Millions
Replimune Group Inc.  13.43 $ 190.874  Millions$ 14.217  Millions
Organovo Holdings Inc.  13.19 $ 31.106  Millions$ 2.358  Millions
Galera Therapeutics Inc.  12.13 $ 117.570  Millions$ 9.694  Millions
Jounce Therapeutics inc.  12.06 $ 173.697  Millions$ 14.400  Millions
Capricor Therapeutics inc.  12.04 $ 10.545  Millions$ 0.876  Millions
Protara Therapeutics Inc.  11.96 $ 6.975  Millions$ 0.583  Millions
Quince Therapeutics Inc.  11.93 $ 106.056  Millions$ 8.892  Millions
Livongo Health Inc   11.64 $ 487.507  Millions$ 41.875  Millions

Date modified: 2022-05-19T12:22:37-04:00

       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AOIX's Profile

Stock Price

AOIX's Financials

Business Description

Fundamentals

Charts & Quotes

AOIX's News

Suppliers

AOIX's Competitors

Customers & Markets

Economic Indicators

AOIX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071